Image of Mark J. Alles

Mark J. Alles serves as Celgene Corporation’s Chairman and Chief Executive Officer. He assumed the role of Chief Executive Officer and joined the Celgene Board of Directors on March 1, 2016. The role of Chairman was added on February 6, 2018.

Mr. Alles served as President and Chief Operating Officer from August 2014 until February 2016, Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, and was also Celgene’s Chief Commercial Officer. Mr. Alles joined Celgene in April 2004 and was Vice President, Global Hematology Marketing until March 2009 when he was promoted to President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Before joining Celgene, he was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rhône-Poulenc Rorer) from 1993-2004.

After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his thirty-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He is a member of the Board of Directors of the Pharmaceutical Manufacturers of America (PhRMA), the European Federation of the Pharmaceutical Industries and Associations (EFPIA), and serves on the Board of Gilda’s Club NYC, a non-profit organization dedicated to helping families of people living with cancer.

Recent Stock Transactions by Mark J. Alles
Date Type Shares Traded Price Range
May 9, 2018 Buy 1,208 82.60
May 4, 2018 Disposition (Non Open Market) 1,519 86.89
May 4, 2018 Option Execute 3,500 n/a
Feb 17, 2018 Disposition (Non Open Market) 2,060 95.26
Feb 17, 2018 Option Execute 7,283 n/a
Feb 8, 2018 Buy 3,260 91.90
Dec 19, 2017 Disposition (Non Open Market) 2,094 107.06
Dec 19, 2017 Option Execute 4,550 n/a
Jul 28, 2017 Disposition (Non Open Market) 1,932 134.10
Jul 28, 2017 Option Execute 4,200 n/a
Feb 14, 2017 Acquisition (Non Open Market) 14,447 n/a
Feb 14, 2017 Disposition (Non Open Market) 6,643 117.02
Dec 2, 2016 Disposition (Non Open Market) 3,018 117.63
Dec 2, 2016 Option Execute 6,560 n/a
Apr 29, 2016 Disposition (Non Open Market) 5,062 103.41
Apr 29, 2016 Option Execute 11,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 25,840 n/a
Feb 12, 2016 Disposition (Non Open Market) 11,889 102.45
Jan 29, 2016 Option Execute 21,938 19.24 - 36.96
Dec 17, 2015 Disposition (Non Open Market) 5,370 112.17
Dec 17, 2015 Option Execute 11,670 n/a
Apr 30, 2015 Disposition (Non Open Market) 5,154 108.06
Apr 30, 2015 Option Execute 11,200 n/a
Mar 1, 2015 Disposition (Non Open Market) 4,078 121.53
Mar 1, 2015 Option Execute 8,334 n/a
Feb 12, 2015 Option Execute 27,505 25.77 - 81.56
Feb 6, 2015 Automatic Sell 117,099 120.68
Feb 6, 2015 Acquisition (Non Open Market) 30,404 n/a
Feb 6, 2015 Disposition (Non Open Market) 13,666 118.75
Feb 6, 2015 Option Execute 107,859 25.77 - 81.56
Feb 12, 2014 Acquisition (Non Open Market) 15,188 n/a
Feb 12, 2014 Disposition (Non Open Market) 6,837 160.54
Dec 27, 2013 Disposition (Non Open Market) 3,501 168.93
Dec 27, 2013 Option Execute 7,777 n/a
Nov 1, 2013 Disposition (Non Open Market) 4,502 151.31
Nov 1, 2013 Option Execute 10,000 n/a
Aug 2, 2013 Sell 5,000 146.47
Aug 2, 2013 Option Execute 15,000 62.35 - 70.63
Jul 31, 2013 Sell 96,406 147.01
Jul 31, 2013 Option Execute 96,406 38.47 - 73.92
Apr 13, 2013 Disposition (Non Open Market) 1,791 123.00
Apr 13, 2013 Option Execute 4,583 n/a
Apr 14, 2012 Disposition (Non Open Market) 902 78.32
Apr 14, 2012 Option Execute 3,056 n/a
Feb 15, 2012 Statement of Ownership 0 n/a
Image of Peter N. Kellogg

Mr. Kellogg is the Executive Vice President and Chief Financial Officer of Celgene, overseeing Financial Planning, Accounting, Tax/Treasury and Investor Relations.  Before joining Celgene, he was Chief Financial Officer and Executive Vice President of Merck & Co. Inc. from 2007 to 2014.  From 2000 to 2007, Mr. Kellogg served as Chief Financial Officer and Executive Vice President of Finance at Biogen, Inc.. Earlier in his career, Peter was a member of the PepsiCo Management for 13 years.  He was the Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc. in 2000 and Senior Vice President and Chief Financial Officer, Frito-Lay International, from 1998 to 2000.  Before that, Peter held various GM and CFO roles in Frito-Lay and Pepsi Cola in the US, Europe, Asia, and Latin America.  Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Booz Allen & Hamilton and Arthur Andersen & Co.  Since 2007, Mr. Kellogg has served on the Board of Directors of Yield10 (formerly Metabolix, Inc), a public bioscience company focused on developing step change improvements to crop yields to enhance global food security.  Peter received his BSE from Princeton University in 1978 and MBA from The Wharton School in 1982.

Recent Stock Transactions by Peter N. Kellogg
Date Type Shares Traded Price Range
May 4, 2018 Disposition (Non Open Market) 1,622 86.89
May 4, 2018 Option Execute 3,500 n/a
Feb 17, 2018 Disposition (Non Open Market) 2,329 95.26
Feb 17, 2018 Option Execute 7,283 n/a
Dec 19, 2017 Disposition (Non Open Market) 1,768 107.06
Dec 19, 2017 Option Execute 3,410 n/a
Oct 27, 2017 Disposition (Non Open Market) 1,088 98.17
Oct 27, 2017 Option Execute 2,100 n/a
Aug 1, 2017 Disposition (Non Open Market) 31,110 135.18
Aug 1, 2017 Option Execute 60,000 n/a
Feb 14, 2017 Acquisition (Non Open Market) 14,684 n/a
Feb 14, 2017 Disposition (Non Open Market) 7,617 117.02
Feb 12, 2016 Acquisition (Non Open Market) 7,822 n/a
Feb 12, 2016 Disposition (Non Open Market) 4,056 102.45
Image of Nadim Ahmed

Mr. Ahmed was promoted to President, Hematology & Oncology Franchise, effective August 23, 2017. Previously, he was President of Worldwide Markets for the Hematology & Oncology Franchise. Mr. Ahmed served as General Manager, US Hematology & Oncology from August 2014 until March 2016. He joined Celgene in 2010 as Global Head of Marketing for Celgene’s Multiple Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global and US Marketing at GlaxoSmithKline. Mr. Ahmed has over 25 years of industry experience. He serves on the Board of Directors of Family Promise, a not-for-profit organization helping homeless families. Mr. Ahmed holds a Bachelor of Science Degree in Pharmacology from University College London, UK and a Master of Science Degree in Information Technology from Loughborough University, UK.


Image of Terrie Curran

Ms. Curran was promoted to President, Inflammation and Immunology Franchise, effective April 1, 2017. Previously, she was Head of Worldwide Markets for the I&I Franchise. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA®. Prior to joining Celgene, she was Merck’s Senior Vice President and GM of the Global Women’s Health franchise from 2009-2013.The UNFPA honored Terrie with an award for the Health and Dignity of Women and Girls in 2012.

Ms. Curran previously served as General Manager for Schering-Plough Switzerland, which subsequently merged with Merck. Prior to moving to Switzerland, Terrie was General Manager of Schering-Plough Australia/New Zealand and served on the Asia Pacific Regional Management Team. She originally joined Schering-Plough (Australia) as Director of Specialty Health Care, where she successfully launched Remicade.  Earlier in her career she served in a variety of sales, marketing and management roles at the former Pharmacia.

Ms. Curran was elected to the board of directors of BioNJ in February 2018. She also serves on the Board of Directors at Myovant Sciences, Ltd and previously served on the board of H. Lundbeck A/S. Ms. Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (BAS) from the University of Technology, Sydney.

Image of Rupert Vessey, MA, BM BCh, FRCP, DPhil

Dr. Vessey serves as President of Research and Early Development.  He joined Celgene in January 2015 as Senior Vice President, Translational Development.  Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics.  Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.  Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM, BCH) and a DPhil (PhD) in Molecular Immunology.  He is an elected Fellow of the Royal College of Physicians.

Recent Stock Transactions by Rupert Vessey, MA, BM BCh, FRCP, DPhil
Date Type Shares Traded Price Range
May 4, 2018 Disposition (Non Open Market) 1,538 86.89
May 4, 2018 Option Execute 3,125 n/a
Feb 2, 2018 Disposition (Non Open Market) 2,673 99.80
Feb 2, 2018 Option Execute 5,623 n/a
Jun 15, 2017 Sell 4,785 120.15 - 120.18
Jun 15, 2017 Option Execute 4,007 100.80 - 104.97
Mar 1, 2017 Sell 4,000 124.42
Feb 2, 2017 Disposition (Non Open Market) 1,995 115.54
Feb 2, 2017 Option Execute 5,623 n/a
Nov 22, 2016 Sell 2,500 123.18
Jun 15, 2016 Statement of Ownership 0 n/a
Jun 15, 2016 Statement of Ownership 0 n/a
Image of Jonathan Biller
Mr. Biller was appointed Executive Vice President and General Counsel, effective July 3, 2018. In this role, he is responsible for Celgene’s global legal function. Mr. Biller joined Celgene in 2011, serving as Senior Vice President, Tax and Treasurer  responsible for Celgene’s global tax and treasury functions including the company’s Celgene’s capital allocation strategy and tax policy. Mr. Biller joined Celgene from Bunge Limited, a publicly traded agriculture and food company, where he was General Counsel, Chief Tax Officer and Secretary from 2008 to 2011.  Prior to Bunge, Mr. Biller held roles of increasing responsibility at Alcon, Inc during which time it was a publicly traded company. He began his legal career at Hopkins & Sutter rising to the level of partner and was also a partner at Foley & Lardner after the firms merged. He also serves on the board of Junior Achievement New Jersey.  Mr. Biller holds a J.D. from Yale Law School and a B.A. from Brown University. 

Stock transaction information provided by EDGAR Online. Celgene Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.